Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

1.4K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

926
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
926

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comorbidity Clusters in Acute Heart Failure: Insights From the AMERICCAASS Registry.

Journal of the American Heart Association·2026
Same author

Characterization of 2,500 Patients with Heart Failure and Analysis of Their Optimal Medical Therapy: Insights from the AMERICCAASS Registry.

Global heart·2025
Same author

Biochemical differences based on sex and clusters of biomarkers in patients with COVID-19: analysis from the CARDIO COVID 19-20 registry.

BMC cardiovascular disorders·2025
Same author

Advancing Cardiac Care: A Registry of Heart Transplantation in Latin America (1968-2022).

Transplantation proceedings·2024
Same author

Association of Abnormal Cardiac Biomarkers and Cardiovascular Complications, with Mortality in Patients with SARS-CoV-2 Infection in Latin America.

Journal of cardiovascular development and disease·2024
Same author

American registry of ambulatory and acute decompensated heart failure (AMERICCAASS registry): Rationale and design.

ESC heart failure·2024

Related Experiment Video

Updated: Jun 29, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

587

[Diabetes and Heart Failure].

Walter Alarco1

  • 1Unidad de Insuficiencia Cardiaca, Trasplante Cardiaco e Hipertensión Pulmonar Instituto Nacional Cardiovascular INCOR. Lima, Perú.

Archivos Peruanos De Cardiologia Y Cirugia Cardiovascular
|April 4, 2024
PubMed
Summary

Diabetes Mellitus (DM) significantly increases heart failure (HF) risk. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) offer crucial benefits for diabetic patients with HF, improving outcomes beyond glycemic control.

Area of Science:

  • Cardiology and Endocrinology
  • Diabetic Cardiomyopathy
  • Cardio-metabolic disease research

Context:

  • Diabetes Mellitus (DM) is a chronic disease linked to severe cardiovascular complications, particularly heart failure (HF).
  • A complex bidirectional relationship exists between DM and HF, with HF often preceding other cardiovascular events in diabetic individuals.
  • DM contributes to HF through both atherosclerosis-mediated and non-atherosclerotic pathways, including direct myocardial effects (Diabetic Cardiomyopathy).

Purpose:

  • To review the mechanisms by which DM leads to HF.
  • To discuss current treatment strategies for HF in diabetic patients.
  • To highlight the role and benefits of SGLT2 inhibitors in managing HF within the diabetic population.

Summary:

  • HF treatment in diabetic patients with reduced ejection fraction mirrors non-diabetic guidelines, focusing on triple neurohumoral blockade.
Keywords:
diabetesheart failure

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

175
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.5K

Related Experiment Videos

Last Updated: Jun 29, 2025

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

587
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

175
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.5K
  • For HF with preserved ejection fraction, specific therapies are still lacking.
  • Sodium-glucose cotransporter 2 inhibitors (SGLT2i) demonstrate significant advantages in diabetic HF patients, offering pleiotropic effects beyond glucose lowering.

    • Impact:

    • SGLT2 inhibitors provide metabolic, hemodynamic, and cellular viability benefits, preventing apoptosis and cell death in the myocardium.
    • Clinical trials like DAPA-HF show SGLT2 inhibitors' efficacy in HF with reduced ejection fraction, marking a therapeutic advancement.
    • These findings suggest SGLT2 inhibitors are pivotal in a new treatment paradigm for diabetic patients with heart failure.